Their established benefits in weight reduction, glycemic control, and cardiovascular protection make them particularly suitable for this high-risk patient population
GLP-1 RAs are known to stimulate insulin and inhibit glucagon, effectively regulating body weight and glucose levels 13
You dont need to be obese to start a GLP-1. In practice, though, you doat least according to the US Food and Drug Administration, which has only approved GLP-1 drugs for people with clinical obesity or Type 2 diabetes and for people who are overweight with weight-related comorbidities
9920299215 Office E/M visits, including management of multiple chronic conditions
If you have blood pressure, kidney, or heart concerns, talk with your clinician before using high-sodium or high-potassium products regularly